Observational studyBreast cancer research and treatment2025
Treatment patterns and clinical outcomes in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer treated with chemotherapy: a large-scale data analysis using the Japanese claims database.
Observational study in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Healthcare Cost Patterns in CDK4/6 Inhibitor-Treated HR+/HER2- Metastatic Breast Cancer.Clinical drug investigation · 2026Article
- Evaluation of adverse drug reactions in cancer-related settings using diverse real-world data.Journal of pharmaceutical health care and sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate treatment patterns and clinical outcomes in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) initiating at least one chemotherapy for metastatic disease in real-world settings in Japan.
methodsIn this observational retrospective cohort study, data of 2697 patients with HR+/HER2- mBC from a Japanese medical claims database who initiated the first chemotherapy in metastatic setting between January 1, 2017, and March 31, 2022, were analyzed. The study assessed treatment patterns, time to next treatment or death (TTNTD), time to treatment discontinuation, medical costs, and adverse events of interest for those receiving first-, second-, and third-line chemotherapies for mBC.
resultsThe most common regimens were S-1 (20.1%), eribulin (12.2%), and paclitaxel + bevacizumab (6.9%) for each line of therapy, respectively. The TTNTD decreased as treatment advanced, with medians of 8.2, 7.3, and 6.0 months for each line. Monthly medical costs were 277.1, 340.9, and 378.4 thousand yen for each line of therapy, respectively. Nausea/vomiting and neutropenia/leukopenia occurred in 62.6% and 20.5% of patients, respectively.
conclusionThis study highlights current chemotherapy practices for HR+/HER2- mBC in Japan, where treatment patterns largely align with clinical guidelines but vary according to patient characteristics. Notably, the TTNTD shortens with successive treatments, and medical costs increase, intensifying the financial burden on patients. These findings indicate unmet needs for improved treatment options that enhance outcomes and reduce patient burden in advanced therapy lines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.